Orasis Pharmaceuticals spent the week spotlighting its presbyopia and pilocarpine-focused strategy ahead of the SECO International 2026 optometry conference. The company is promoting a live “myth-busting” educational session on presbyopia eye drops, led by optometrists with FAAO credentials and accessible both in person and via livestream.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Multiple LinkedIn updates emphasize Orasis’s presence at SECO 2026 Booth 133, underscoring efforts to deepen engagement with eye-care professionals. The company is positioning education and clinical dialogue as key tools to address misconceptions around pilocarpine-based treatments and to support prescriber confidence.
Orasis also highlighted a breakfast symposium specifically aimed at dispelling myths surrounding pilocarpine, a core component of its presbyopia strategy. By anchoring the session with key opinion leaders, the company is seeking to shape clinical perceptions and strengthen its standing in an increasingly competitive presbyopia-drop market.
In addition, Orasis is backing its educational push with scientific content, including a poster session on the concentration-dependent effects of low-concentration pilocarpine. This focus on dose and formulation may help differentiate its approach and provide clinicians with data-driven context for prescribing decisions.
The company is directing clinicians to safety information and materials outlining the benefits and risks of its therapy, signaling attention to regulatory expectations and appropriate labeling. This risk-benefit framing may support responsible adoption as presbyopia drops gain broader visibility among practitioners.
From a strategic standpoint, Orasis’s activity at SECO 2026 points to ongoing commercial preparation and brand-building in front of target prescribers. While financial outcomes will depend on future clinical, regulatory, and market milestones, the week’s outreach enhances clinical visibility and could lay groundwork for stronger competitive positioning over time.
Overall, Orasis Pharmaceuticals used the week to reinforce its educational and scientific profile around pilocarpine and presbyopia therapy, leveraging SECO 2026 as a platform to engage clinicians, address myths, and support future market adoption efforts.